Skip to main content

Publications

featured publications

  • Physical activity and factor VIII levels in patients with haemophilia: A real-world prospective observational study.

    Haemophilia : the official journal of the World Federation of Hemophilia

    Authors: Fabian Tomschi, Jamil Hmida, Steffen Herzig, Pia Ransmann, Marius Brühl, Alexander Schmidt, Marie Herzig, Georg Goldmann, Andreas C Strauß, Johannes Oldenburg, Heinrich Richter, Thomas Hilberg

  • The role of microRNAs in defining LSECs cellular identity and in regulating gene expression.

    Frontiers in genetics

    Authors: Muhammad Ahmer Jamil, Rawya Al-Rifai, Nicole Nuesgen, Janine Altmüller, Johannes Oldenburg, Osman El-Maarri

  • Genetic Landscape of Factor VII Deficiency: Insights from a Comprehensive Analysis of Pathogenic Variants and Their Impact on Coagulation Activity.

    International journal of molecular sciences

    Authors: Barbara Preisler, Behnaz Pezeshkpoor, Anja Merzenich, Sandra Ohlenforst, Heiko Rühl, Vytautas Ivaškevičius, Ute Scholz, Hagen Bönigk, Wolfgang Eberl, Barbara Zieger, Anna Pavlova, Johannes Oldenburg

  • Fibrinolysis biomarker, thrombin, and activated protein C level alterations after coagulation activation depend on type of thrombophilia and clinical phenotype.

    Research and practice in thrombosis and haemostasis

    Authors: Sara Reda, Nadine Schwarz, Jens Müller, Hannah L McRae, Johannes Oldenburg, Bernd Pötzsch, Heiko Rühl

  • Hemostatic imbalance induced by tamoxifen in estrogen receptor-positive breast cancer patients: An observational study.

    International journal of laboratory hematology

    Authors: Marie Didembourg, Sara Reda, Johannes Oldenburg, Heiko Rühl, Jonathan Douxfils, Laure Morimont

  • Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU.

    Blood advances

    Authors: Kathelijn Fischer, Gili Kenet, Karin Kurnik, Manuel Carcao, Johannes Oldenburg, Torben Stamm-Mikkelsen, Ana Rosa Cid Haro, Minna Koskenvuo, Jan Blatny, Christoph Königs

  • Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.

    Research and practice in thrombosis and haemostasis

    Authors: Anna Kiialainen, Joanne I Adamkewicz, Claire Petry, Johannes Oldenburg, Steven W Pipe, Guy Young, Johnny Mahlangu, Michaela Lehle, Markus Niggli, Giancarlo Castaman, Víctor Jiménez-Yuste, Midori Shima, Claude Négrier, Christophe Schmitt

  • Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial.

    Blood

    Authors: Steven W Pipe, Peter W Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Victor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat

  • Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.

    Hamostaseologie

    Authors: Christian Pfrepper, Robert Klamroth, Johannes Oldenburg, Katharina Holstein, Hermann Eichler, Christina Hart, Patrick Moehnle, Kristina Schilling, Karolin Trautmann-Grill, Mohammed Alrifai, Cihan Ay, Wolfgang Miesbach, Paul Knoebl, Andreas Tiede

  • Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.

    European journal of haematology

    Authors: Mark T Reding, María Teresa Álvarez-Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg